Subtype
Urinary System Carcinoma
CI-CAN-00004182Explore in graph →
670 active trials25 approved drugs87 evidence items
- NCIt
- C181197
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004182Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (391)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03874455 | Tazemetostat Expanded Access Program for Adults With Solid Tumors | no longer available | — | — | Epizyme, Inc.INDUSTRY | 0 | Jul 2, 2026 | clinicaltrials |
| NCT06090331 | 89Zr-DFO-girentuximab Expanded Access Program (EAP) | no longer available | — | — | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT03554434 | An Expanded Access Program for AM0010 (Pegilodecakin) | no longer available | — | — | Eli Lilly and CompanyINDUSTRY | 0 | Mar 2, 2020 | clinicaltrials |
| NCT01473043 | Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment | no longer available | — | — | PfizerINDUSTRY | 2 | May 30, 2014 | clinicaltrials |
| NCT00655252 | Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 13 | Aug 19, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Jul 2, 2026source: clinicaltrials